查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654380

美國醫藥市場規模、佔有率和趨勢分析報告：按分子、產品類型、給藥途徑、疾病、年齡層、分銷管道、細分預測，2025-2030 年

U.S. Pharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Product, By Type, By Route Of Administration, By Disease, By Age Group, By Distribution Channel, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國醫藥市場規模及趨勢

預計 2024 年美國醫藥市場規模為 6,343.2 億美元，到 2030 年將達到 8,839.7 億美元，2025 年至 2030 年的複合年成長率為 5.72%。這種成長是由於慢性病患病率上升、老齡人口成長、政府機構增加醫療保健支出以及普遍努力提高藥品的可負擔性和可獲得性。

由於治療方法的進步和強大的產品平臺，美國製藥業正在經歷強勁成長。標靶治療、生技藥品和個人化醫療的發展正在重塑治療模式，並為癌症、自體免疫和遺傳性疾病等複雜疾病提供更有效的解決方案。基因療法和基於 RNA 的療法正在獲得 FDA核准，例如治療遺傳性視網膜疾病和某些癌症，有助於推動產業發展。用於治療某些癌症的CAR-T細胞療法等尖端藥物的核准表明市場對精準醫療的關注度日益提高，為治療以前無法治癒的疾病帶來了希望。顯著的進展包括免疫腫瘤療法的持續進步，重新定義了癌症治療。

在美國醫藥市場，GLP-1受體促效劑及GLP-1/GIP雙重促效劑的突破性臨床結果為肥胖治療樹立了新的標準。 GLP-1受體促效劑和GLP-1/GIP雙重促效劑作為將帶來前所未有的臨床效果的突破性治療方法而備受關注。這些藥物，包括Semaglutide和替澤帕肽，已被證明可以使體重減輕高達 25%，遠遠超過先前只能達到 7% 左右減重效果的藥物類別。這項突破重塑了患者和醫療保健提供者的肥胖治療模式，為長期難以控制的疾病提供了可行的醫療解決方案。加上數位健康工具的進步，這些治療現在已成為將藥物治療與技術、行為指導和個人化介入相結合的綜合護理模式的一部分。這種綜合方法不僅能解決肥胖問題，還能改善患者的整體治療效果，為克服美國重大公共衛生挑戰指明了方向。

美國醫藥品研究開發費用是市場成長的重要驅動力，該領域不斷投資於發現和開發新的治療方法。 2023年，美國製藥公司在研發上的投入將超過800億美元，而且這個數字每年都在增加。強生、默克、禮來等大公司認知到開發創新藥物以應對人口老化和慢性病增加的重要性，並將公司收益的很大一部分用於研發。

如此高水準的投資正在推動腫瘤學、免疫學和罕見疾病等多個領域的突破性治療方法的發現。根據牛津學術雜誌的報導，到2023年，美國的藥品支出將增加13.6%，達到7,225億美元。這一成長是由利用率增加 6.5%、新藥增加 4.2% 以及價格上漲 2.9% 所推動的。 2023 年最暢銷的藥物是Semaglutide，其次是Adalimumab和Apixaban。此外，到 2023 年，非聯邦醫院的藥品支出預計將下降 1.1% 至 371 億美元，而診所的藥品支出將增加 15.0% 至 1,357 億美元。診所的成長是由利用率的提高所推動的，僅受到新產品和價格變化的輕微影響。對於非聯邦醫院，利用率降低導致支出降低，但新藥和價格的影響很小。預計 2024 年將推出的幾種新藥將繼續推動支出，尤其是在專科、內分泌和腫瘤治療領域。

新型創新藥物不斷湧入市場也是美國醫藥市場發展的主要動力之一。隨著患者和醫療保健提供者越來越意識到新療法的有效性，對具有更好結果和更少副作用的最先進治療的需求也日益增加。特別是生技藥品、基因治療、免疫治療對癌症、自體免疫疾病等的應用日益廣泛。例如，單株抗體（如用於免疫腫瘤學的抗體）的快速應用已經改變了治療格局，市場領導者 Keytruda 和Opdivo 的與前一年同期比較實現了令人印象深刻的成長。近日，2024年9月，API研發中心接受了1,400萬美元的戰略資金，旨在加強美國製藥獨立性。這筆資金將支持美國關鍵活性藥物原料藥(API) 製造能力的發展，提高供應鏈的彈性並減少對海外來源的依賴。這項舉措符合加強國內生產、提高國家安全和確保持續獲得​​基本藥物的努力。

然而，主要藥物的專利到期是美國製藥業發展的一大限制因素。當專利到期時，學名藥往往會進入市場，導致品牌藥銷售量急劇下降。例如，2023年1月，艾伯維的重磅藥物Humira（Adalimumab）的專利將到期，該藥物年銷售額超過200億美元，為生物學名藥的競爭打開了大門。從品牌藥物轉變為學名藥的轉變將減少原產公司的市場佔有率，從而嚴重影響其收益來源。整體市場動態也將受到學名藥定價壓力的影響，迫使原產公司降低價格或尋找新的市場利基。這種轉變在生技藥品市場尤為明顯，其中Enbrel和Herceptin等主要產品的專利已到期，為更便宜的替代品鋪平了道路。

目錄

第 1 章美國醫藥市場：調查方法與範圍

第 2 章美國醫藥市場：執行摘要

  • 市場概述
  • 段簡介
  • 競爭格局概況

第 3 章美國醫藥市場的變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 波特五力分析
  • PESTLE分析

第 4 章：美國醫藥市場按分子類型、展望、估計和趨勢分析

  • 美國藥物市場：分子類型變異分析
  • 生技藥品和生物相似藥（聚合物）
  • 傳統藥物（小分子）

第 5 章：美國醫藥市場：按產品分類的估計和趨勢分析

  • 美國醫藥市場：產品波動分析
  • 品牌
  • 非專利的

第6章美國醫藥市場類型、估計與趨勢分析

  • 美國醫藥市場：類型變化分析
  • 處方箋
  • 在商店

第 7 章美國醫藥市場：疾病展望、估計與趨勢分析

  • 美國醫藥市場：疾病展望與趨​​勢分析
  • 心血管疾病
  • 癌症
  • 糖尿病
  • 感染疾病
  • 神經系統疾病
  • 呼吸系統疾病
  • 自體免疫疾病
  • 精神疾病
  • 胃腸道疾病
  • 女性健康疾病
  • 遺傳疾病及罕見遺傳疾病
  • 皮膚病
  • 肥胖
  • 腎臟疾病
  • 肝臟疾病
  • 血液系統疾病
  • 眼部疾病
  • 不孕不育
  • 內分泌失調
  • 過敏
  • 其他

第 8 章：美國藥品市場按給藥途徑分類的估計和趨勢分析

  • 美國醫藥市場：給藥途徑變化分析
  • 口服
  • 局部的
  • 腸外
  • 吸入
  • 其他

第9章美國醫藥市場：按年齡層別分類的估計和趨勢分析

  • 美國醫藥市場：基於年齡的趨勢分析
  • 兒童和青少年
  • 成人
  • 老年人

第 10 章：美國醫藥市場分銷管道組別、估計與趨勢分析

  • 美國醫藥市場：通路組變化分析
  • 醫院藥房
  • 零售藥局
  • 其他

第11章 競爭格局

  • 公司分類
  • 戰略地圖
    • 新產品發布
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 2024 年主要企業的市場佔有率分析
  • 公司熱圖分析
  • 公司簡介
    • F. HOFFMANN-LA ROCHE LTD
    • NOVARTIS AG
    • ABBVIE INC.
    • JOHNSON &JOHNSON SERVICES, INC.
    • MERCK &CO., INC.
    • PFIZER INC.
    • BRISTOL-MYERS SQUIBB COMPANY
    • SANOFI
    • GSK PLC.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
Product Code: GVR-4-68040-210-9

U.S. Pharmaceutical Market Size & Trends:

The U.S. pharmaceutical market size was estimated at USD 634.32 billion in 2024 and is expected to grow at a CAGR of 5.72% from 2025 to 2030, to reach an estimated value of USD 883.97 billion by 2030. This growth can be attributed to the rising prevalence of chronic diseases, increasing geriatric population, growing healthcare expenditure by government organizations, and extensive efforts to improve the affordability & accessibility of pharmaceuticals.

The U.S. pharmaceutical industry has experienced significant growth due to advancements in therapeutics and a robust product pipeline. The development of targeted therapies, biologics, and personalized medicine has reshaped treatment model, offering more effective solutions for complex conditions such as cancer, autoimmune diseases, and genetic disorders. Gene therapies and RNA-based treatments, like those for inherited retinal diseases and certain types of cancers, have gained FDA approvals, contributing to the industry's momentum. The approval of cutting-edge drugs such as CAR-T cell therapies for certain cancers exemplifies the market's growing focus on precision medicine, offering hope for previously untreatable conditions. A notable advancement is the continued progression in immuno-oncology treatments, which are redefining cancer care.

In the U.S. market for pharmaceuticals, the transformative clinical outcomes of GLP-1 receptor agonists and GLP-1/GIP dual agonists, have set a new benchmark for obesity treatment. As they are emerged as transformative therapies, delivering unprecedented clinical results. These medications, such as semaglutide and tirzepatide, have demonstrated weight loss of up to 25%, significantly outperforming earlier drug classes, which achieved only about 7% weight reduction. This breakthrough has reshaped the obesity treatment paradigm for both patients and providers, offering a viable medical solution to a condition long viewed as difficult to manage. Coupled with advances in digital health tools, these therapies are part of integrated care models that combine pharmacological treatments with technology, behavioral coaching, and personalized interventions. This comprehensive approach not only addresses obesity but also improves overall patient outcomes, presenting a credible pathway to overcoming a major public health challenge in the U.S.

Pharmaceutical R&D spending in the U.S. has been a pivotal driver of market growth, with the sector continuously investing in the discovery and development of new therapies. In 2023, pharmaceutical companies in the U.S. spent over USD 80 billion on R&D, a figure that continues to rise annually. Major companies like Johnson & Johnson, Merck, and Eli Lilly have earmarked significant portions of their revenues to R&D, recognizing the importance of developing innovative drugs to meet the demands of an aging population and the increasing prevalence of chronic diseases.

This high level of investment fuels the discovery of breakthrough therapies across various segments, including oncology, immunology, and rare diseases. According to an article by oxford Academic, in 2023, U.S. pharmaceutical spending rose by 13.6% to reach USD 722.5 billion. This increase was driven by a 6.5% rise in utilization, a 4.2% boost from new drugs, and a 2.9% uptick in prices. The top-selling drug of 2023 was semaglutide, followed by adalimumab and apixaban. Furthermore, In 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion. Clinic growth was driven by higher utilization, with a minor impact from new products and price changes. In nonfederal hospitals, lower utilization led to reduced spending, while new drugs and prices had a modest influence. Several new drugs expected in 2024, especially in specialty, endocrine, and cancer treatments, will continue to drive spending.

The growing market adoption of innovative and modern medicines is another key driver of the U.S. pharmaceutical market. As patients and healthcare providers become more aware of the effectiveness of new treatments, there is an increasing demand for cutting-edge therapies that offer better outcomes and fewer side effects. The uptake of biologics, gene therapies, and immunotherapies in oncology, autoimmune diseases, and other areas has been particularly notable. For example, the rapid adoption of monoclonal antibodies, such as those used in immuno-oncology, has transformed the treatment landscape, with market leaders like Keytruda and Opdivo showing impressive year-on-year sales growth. Recently, in September 2024, the API Innovation Center received USD 14 million in strategic funding aimed at strengthening U.S. pharmaceutical independence. The funding will support the development of critical Active Pharmaceutical Ingredients (API) manufacturing capabilities within the U.S., enhancing resilience in the supply chain and reducing reliance on foreign sources. This initiative aligns with efforts to bolster domestic production, improve national security, and ensure consistent access to essential medicines.

However, Patent expiration of key pharmaceutical drugs has emerged as a significant restraint for the growth of the U.S. pharmaceutical industry. Once patents expire, generic versions of these drugs can enter the market, often leading to a sharp decline in sales for the original branded drugs. For instance, in January 2023, the patent for AbbVie's blockbuster drug Humira (adalimumab), which generated over USD 20 billion in annual sales, expired, allowing biosimilars to compete. The shift from branded to generic drugs reduces the market share of originator companies and significantly impacts their revenue streams. The overall market dynamics are also affected by the pricing pressure brought on by these generics, forcing branded companies to reduce prices or find new market niches. This change is particularly evident in the biologics market, where patents for key products like Enbrel and Herceptin have expired, opening the door for cheaper alternatives.

U.S. Pharmaceutical Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the U.S. pharmaceutical market report based on molecule, product, type, disease, route of administration, age group, and distribution channel:

  • Molecule Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Biologics & Biosimilars (Large Molecules)
    • Monoclonal Antibodies
    • Vaccines
    • Cell & Gene Therapy
    • Others
  • Conventional Drugs (Small Molecules)
  • Product Outlook (Revenue, USD Billion, 2018 - 2030)
  • Branded
  • Generic
  • Type Outlook (Revenue, USD Billion, 2018 - 2030)
  • Prescription
  • OTC
  • Disease Outlook (Revenue, USD Billion, 2018 - 2030)
  • Cardiovascular diseases
  • Cancer
  • Diabetes
  • Infectious diseases
  • Neurological disorders
  • Respiratory diseases
  • Autoimmune diseases
  • Mental health disorders
  • Gastrointestinal disorders
  • Women's Health Diseases
  • Genetic and Rare genetic diseases
  • Dermatological conditions
  • Obesity
  • Renal diseases
  • Liver conditions
  • Hematological disorders
  • Eye conditions
  • Infertility conditions
  • Endocrine disorders
  • Allergies
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
  • Oral
    • Tablet Capsule
    • Suspensions
    • Other
  • Topical
  • Parenteral
    • Intravenous
    • Intramuscular
  • Inhalations
  • Other
  • Age Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Children & Adolescents
  • Adults
  • Geriatric
  • Distribution Channel Group Outlook (Revenue, USD Billion, 2018 - 2030)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. U.S. Pharmaceutical Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Objectives
    • 1.3.1. Objective - 1
    • 1.3.2. Objective - 2
    • 1.3.3. Objective - 3
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information or Data Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations

Chapter 2. U.S. Pharmaceutical Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Pharmaceutical Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing healthcare spending by the government
      • 3.2.1.2. Improving affordability driven by rising per capita income
      • 3.2.1.3. Increasing awareness about healthcare among the population
      • 3.2.1.4. Increasing access to innovative and modern medicines
      • 3.2.1.5. Demographic and lifestyle changes leading to rising prevalence of chronic diseases
      • 3.2.1.6. Rising chronic diseases and geriatric population
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. COVID-19 pandemic
      • 3.2.2.2. Intensification of competition from generic and biosimilar drugs
      • 3.2.2.3. Increasing price-sensitivity of customers for non-reimbursed drugs
      • 3.2.2.4. Increasing barriers to market access and decreasing R&D productivity of pharma companies
  • 3.3. Porter's Five Forces Analysis
  • 3.4. PESTLE Analysis

Chapter 4. U.S. Pharmaceutical Market: Molecule Type Outlook Estimates & Trend Analysis

  • 4.1. Molecule Type Outlook: Movement Analysis
  • 4.2. Biologics & Biosimilars (Large Molecules)
    • 4.2.1. Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.1.1 Biologics & Biosimilars (Large Molecules)
      • 4.2.1.2 Biologics & Biosimilars Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.1.2.1 Monoclonal Antibodies
        • 4.2.1.2.2 Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.3.1 Vaccines
      • 4.2.3.2 Vaccines Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
        • 4.2.3.1.1 Cell & Gene Therapy
        • 4.2.3.3.2 Cell & Gene Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
      • 4.2.5.1 Others
      • 4.2.5.2 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3. Conventional Drugs (Small Molecules)
    • 4.3.1. Conventional Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. U.S. Pharmaceutical Market: Product Estimates & Trend Analysis

  • 5.1. U.S. Pharmaceutical Market: Product Movement Analysis
  • 5.2. Branded
    • 5.2.1. Branded Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.3. Generic
    • 5.3.1. Generic Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. U.S. Pharmaceutical Market: Type Estimates & Trend Analysis

  • 6.1. U.S. Pharmaceutical Market: Type Movement Analysis
  • 6.2. Prescription
    • 6.2.1. Prescription Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.3. OTC
    • 6.3.1. OTC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. U.S. Pharmaceutical Market: Disease Outlook Estimates & Trend Analysis

  • 7.1. U.S. Pharmaceutical Market: Disease Outlook Movement Analysis
  • 7.2. Cardiovascular diseases
    • 7.2.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Cancer
    • 7.3.1. Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Diabetes
    • 7.4.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Infectious diseases
    • 7.5.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Neurological disorders
    • 7.6.1. Neurological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Respiratory diseases
    • 7.7.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. Autoimmune diseases
    • 7.8.1. Autoimmune Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.9. Mental health disorders
    • 7.9.1. Mental Health Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.10. Gastrointestinal disorders
    • 7.10.1. Gastrointestinal Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.11. Women's Health Diseases
    • 7.11.1. Women's Health Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.12. Genetic and Rare genetic diseases
    • 7.12.1. Genetic and Rare Genetic Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.13. Dermatological conditions
    • 7.13.1. Dermatological Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.14. Obesity
    • 7.14.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.15. Renal diseases
    • 7.15.1. Renal Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.16. Liver conditions
    • 7.16.1. Liver Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.17. Hematological disorders
    • 7.17.1. Hematological Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.18. Eye conditions
    • 7.18.1. Eye Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.19. Infertility conditions
    • 7.19.1. Infertility Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.20. Endocrine disorders
    • 7.20.1. Endocrine Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.21. Allergies
    • 7.21.1. Allergies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.22. Others
    • 7.22.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. U.S. Pharmaceutical Market: Route of Administration Estimates & Trend Analysis

  • 8.1. U.S. Pharmaceutical Market: Route of Administration Movement Analysis
  • 8.2. Oral
    • 8.2.1. Oral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.3. Topical
    • 8.3.1. Topical Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.4. Parenteral
    • 8.4.1. Parenteral Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
      • 8.4.1.1. Intravenous
      • 8.4.1.2. Intramuscular
  • 8.5. Inhalations
    • 8.5.1. Inhalations Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.6. Other
    • 8.6.1. Other Route Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. U.S. Pharmaceutical Market: Age Group Estimates & Trend Analysis

  • 9.1. U.S. Pharmaceutical Market: Age Group Movement Analysis
  • 9.2. Children & Adolescents
    • 9.2.1. Children & Adolescents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.3. Adults
    • 9.3.1. Adults Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 9.4. Geriatric
    • 9.4.1. Geriatric Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 10. U.S. Pharmaceutical Market: Distribution Channel Group Estimates & Trend Analysis

  • 10.1. U.S. Pharmaceutical Market: Distribution Channel Group Movement Analysis
  • 10.2. Hospital Pharmacy
    • 10.2.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.3. Retail Pharmacy
    • 10.3.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 10.4. Others
    • 10.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
  • 11.2. Strategy Mapping
    • 11.2.1. NEW PRODUCT LAUNCH
    • 11.2.2. PARTNERSHIPS
    • 11.2.3. ACQUISITION
    • 11.2.4. COLLABORATION
    • 11.2.5. FUNDING
  • 11.3. Key Company Market Share Analysis, 2024
  • 11.4. Company Heat Map Analysis
  • 11.5. Company Profiles
    • 11.5.1. F. HOFFMANN-LA ROCHE LTD
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Financial Performance
      • 11.5.1.3. Product Benchmarking
      • 11.5.1.4. Strategic Initiatives
    • 11.5.2. NOVARTIS AG
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Financial Performance
      • 11.5.2.3. Product Benchmarking
      • 11.5.2.4. Strategic Initiatives
    • 11.5.3. ABBVIE INC.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Financial Performance
      • 11.5.3.3. Product Benchmarking
      • 11.5.3.4. Strategic Initiatives
    • 11.5.4. JOHNSON & JOHNSON SERVICES, INC.
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Financial Performance
      • 11.5.4.3. Product Benchmarking
      • 11.5.4.4 Strategic Initiatives
    • 11.5.5. MERCK & CO., INC.
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Financial Performance
      • 11.5.5.3. Product Benchmarking
      • 11.5.5.4. Strategic Initiatives
    • 11.5.6. PFIZER INC.
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Financial Performance
      • 11.5.6.3. Product Benchmarking
      • 11.5.6.4. Strategic Initiatives
    • 11.5.7. BRISTOL-MYERS SQUIBB COMPANY
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Financial Performance
      • 11.5.7.3. Product Benchmarking
      • 11.5.7.4. Strategic Initiatives
    • 11.5.8. SANOFI
      • 11.5.8.1. Company Overview
      • 11.5.8.2. Financial Performance
      • 11.5.8.3. Product Benchmarking
      • 11.5.8.4. Strategic Initiatives
    • 11.5.9. GSK PLC.,
      • 11.5.9.1. Company Overview
      • 11.5.9.2. Financial Performance
      • 11.5.9.3. Product Benchmarking
      • 11.5.9.4. Strategic Initiatives
    • 11.5.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      • 11.5.10.1. Company Overview
      • 11.5.10.2. Financial Performance
      • 11.5.10.3. Product Benchmarking
      • 11.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Pharmaceutical Market, By Molecule Type, 2018 - 2030 (USD Billion)
  • Table 4 U.S. Pharmaceutical Market, By Product, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Pharmaceutical Market, By Type, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Pharmaceutical Market, By Disease, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. Pharmaceutical Market, By Age Group, 2018 - 2030 (USD Billion)
  • Table 9 U.S. Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain-Based Sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 U.S. Pharmaceutical Market Segmentation
  • FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • FIG. 11 Penetration & Growth Prospect Mapping
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 U.S. Pharmaceutical Market: Product outlook and key takeaways
  • FIG. 15 U.S. Pharmaceutical Market: Product movement analysis & market share 2024 & 2030
  • FIG. 16 Branded U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 17 Generics U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 18 U.S. Pharmaceutical Market: Type outlook and key takeaways
  • FIG. 19 U.S. Pharmaceutical Market: Type movement analysis & market share 2024 & 2030
  • FIG. 20 Prescription U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 21 OTC U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 22 U.S. Pharmaceutical Market: Therapeutic category outlook and key takeaways
  • FIG. 23 U.S. Pharmaceutical Market: Therapeutic category movement analysis & market share 2024 & 2030
  • FIG. 24 Oncology U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 25 Anti-infectives U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 26 Cardiovascular diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 27 CNS disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 28 Metabolic disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 29 GI disorders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 30 Respiratory diseases U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 31 Others U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 32 U.S. Pharmaceutical Market: Formulation outlook and key takeaways
  • FIG. 33 U.S. Pharmaceutical Market: Formulation movement analysis & market share 2024 & 2030
  • FIG. 34 Tablets U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 35 Capsules U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 36 Injectables U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 37 Sprays U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 38 Suspensions U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 39 Powders U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 40 Others formulation U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 41 U.S. Pharmaceutical Market: Age group outlook and key takeaways
  • FIG. 42 U.S. Pharmaceutical Market: Age group movement analysis & market share 2024 & 2030
  • FIG. 43 Children & Adolescents U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 44 Adults U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)
  • FIG. 45 Geriatric U.S. Pharmaceutical Market, 2018 - 2030 (USD Billion)